BiotechTube

sparsentan + Irbesartan

Phase 3Active
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Segmental Glomerulosclerosis

Conditions

Focal Segmental Glomerulosclerosis

Trial Timeline

Apr 17, 2018 → Feb 1, 2026

NCT ID
NCT03493685

About sparsentan + Irbesartan

sparsentan + Irbesartan is a phase 3 stage product being developed by Travere Therapeutics for Focal Segmental Glomerulosclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT03493685. Target conditions include Focal Segmental Glomerulosclerosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03493685Phase 3Active

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
85
DapagliflozinAstraZenecaApproved
85
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
52
CCX140-BAmgenPhase 2
51
PF-06730512PfizerPhase 2
51
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
84
VX-147Vertex PharmaceuticalsPhase 2
51
VX-147Vertex PharmaceuticalsPhase 1
32
IXPVertex PharmaceuticalsPhase 1
32
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
51
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
32
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
51
VivaglobinCSLPhase 2
51
UCB0942UCBPhase 2
49
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
82
Brivaracetam + BrivaracetamUCBPhase 2
49
LacosamideUCBPhase 2
49
UCB0942 + UCB0942 + PlaceboUCBPhase 2
49
LacosamideUCBPre-clinical
20
ARGX-117ArgenxPhase 2
49

Other Products from Travere Therapeutics

SparsentanApproved
80
PegtibatinasePhase 3
72
Fosmetpantotenate + PlaceboPhase 3
72
sparsentan + irbesartan + DapagliflozinPhase 3
72
PegtibatinasePhase 3
72